Immunome, Inc. (IMNM) - Stock Analysis
Last updated: Mar 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Large cash reserve ⢠Persistent cash burn ⢠Material dilution IMNM has a strong balance sheet with $653.7M cash and minimal debt but is financially unsustainable short-termâheavy R&D-driven operating losses, negative FCF, and material dilution mean it relies on external financing to operate.
Price Behavior
Key Price Behavior Insights: ⢠Below lastâmonth average ⢠Tested support ⢠Failed to regain highs Support Level: $20.90â$21.50 Resistance Level: $22.50 (initial); $24.00â$25.00 (strong) IMNM is in a shortâterm downtrend, trading below its lastâmonth average (~$22.5) after peaking at $24.93 and testing support around $20.9â$21.5, so a break below ~$20.9 would be bearish while reclaiming $24â$25 would shift momentum bullish.
Sentiment & News
Key News Insights: ⢠Clinical milestone ⢠Investor churn ⢠Hiring incentives Immunome reported positive Phase 3 varegacestat data supporting a planned NDA and paired that clinical milestone with investor presentations, new-employee option grants, and mixed investor flows (Redmile buying, Opaleye exiting).
AI Summary
Immunome has moved from a pure discovery biotech to a balance-sheet-backed, clinic-stage company where its ~$654M cash runway (â$5.78/share) and financing/dilution dynamicsânot just clinical binary outcomesânow primarily determine near-term valuation. The key action is to monitor NDA/regulatory feedback, cash runway trajectory, and any further equity raises closely, because failure to derisk commercialization or control burn will rapidly re-price optionality.
Description
Immunome, Inc. is a biopharmaceutical firm that discovers and develops monoclonal antibody therapeutics for oncology and infectious diseases. Its lead oncology candidate, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint implicated in tumor immune evasion, and the company also maintains an antibody cocktail program for SARS-CoV-2. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | IMNM | Immunome, Inc. | Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity. | Closed | +12.9% |